Cary J. Claiborne - 23 May 2023 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Role
Chief Executive Officer, Director
Signature
/s/ Cary J. Claiborne
Issuer symbol
ADIL
Transactions as of
23 May 2023
Net transactions value
$0
Form type
4
Filing time
25 May 2023, 16:36:03 UTC
Previous filing
20 Sep 2022
Next filing
29 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADIL Common Stock Award $0 +420,000 +38% $0.000000 1,520,000 23 May 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADIL Stock Option (Right to Buy) Award $0 +300,000 $0.000000 300,000 23 May 2023 Common Stock 300,000 $0.3025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.